Second-line lenvatinib in patients with recurrent endometrial cancer

Ignace Vergote, Matthew A. Powell, Michael G. Teneriello, David S. Miller, Agustin A. Garcia, Olga N. Mikheeva, Mariusz Bidzinski, Cristina Ligia Cebotaru, Corina E. Dutcus, Min Ren, Tadashi Kadowaki, Yasuhiro Funahashi, Richard T. Penson

Research output: Contribution to journalArticle

Abstract

Objective: This study assessed the efficacy of lenvatinib, a multitargeted tyrosine kinase inhibitor, as second-line therapy in patients with unresectable endometrial cancer. The primary end point was the objective response rate (ORR) as assessed by independent radiologic review (IRR). Secondary end points included median progression-free survival (PFS), overall survival (OS), and clinical benefit rate. Exploratory end points examined the association of baseline levels of plasma biomarkers (50 circulating cytokine and/or angiogenic factors measured by immunoassays) with efficacy outcomes. Methods: An international, open-label, single-arm, multicenter, phase 2 trial was conducted. Eligible patients had histologically confirmed unresectable endometrial cancer that relapsed after 1 prior systemic platinum-based chemotherapy. Patients received once-daily oral lenvatinib 24 mg in a 28-day dosing cycle. Results: There were 133 patients in the study. By IRR, 19 patients had a confirmed objective response for an ORR of 14.3% (95% CI: 8.8–21.4). Durable stable disease (≥23 weeks) was observed in 31 patients (23.3%) and the clinical benefit rate was 37.6% (95% CI: 29.3–46.4). Median PFS was 5.6 months (95% CI: 3.7–6.3), and median OS was 10.6 months (95% CI: 8.9–14.9). The most common (any grade) treatment-related adverse events were fatigue/asthenia (48%), hypertension (49%), nausea/vomiting (32%), decreased appetite (32%), and diarrhea (31%). Lower baseline levels of angiopoietin-2 were associated with longer PFS, OS, and a higher ORR. Conclusions: Patients with recurrent endometrial cancer treated with second-line lenvatinib experienced modest antitumor activity and treatment was generally well tolerated, with a safety profile consistent with previous studies.

Original languageEnglish (US)
Pages (from-to)575-582
Number of pages8
JournalGynecologic oncology
Volume156
Issue number3
DOIs
StatePublished - Mar 2020

Keywords

  • Endometrial cancer
  • Lenvatinib
  • Multikinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Second-line lenvatinib in patients with recurrent endometrial cancer'. Together they form a unique fingerprint.

  • Cite this

    Vergote, I., Powell, M. A., Teneriello, M. G., Miller, D. S., Garcia, A. A., Mikheeva, O. N., Bidzinski, M., Cebotaru, C. L., Dutcus, C. E., Ren, M., Kadowaki, T., Funahashi, Y., & Penson, R. T. (2020). Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecologic oncology, 156(3), 575-582. https://doi.org/10.1016/j.ygyno.2019.12.039